A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC).

Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to ...

Earlier this year, doctors at Veterans Affairs hospitals in Pennsylvania sounded an alarm. Sweeping cuts imposed by the Trump administration, they told higher-ups in an email, were causing “severe and ...

Early stage diagnosis offers the most favorable prognosis for cancer treatment. Although conventional screening methods ...

The Hall of Famer doesn’t want to coach, and he doesn’t want to work full time. He just wants to be heard. But has the NBA ...

Don't ignore those symptoms. Head and neck cancers are far more manageable, and often curable, with less aggressive treatment ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

A new treatment delivery for Head and Neck Cancer Dr. Geraldine LunaConsultant, Asian Cancer Institute | Asian Hospital and Medical CenterCancer comes in ...

The Trump administration's cuts are jeopardizing veterans' health care, according to a ProPublica report. VA hospitals are ...

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...